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comparative impact of these strategies on retardation of the 
progression of kidney disease, they should certainly change 
practice in the interim. (Ann Intern Med 2008; 148: 30–48)
Lynda Szczech
Low-dose calcineurin inhibitor 
protects against nephrotoxicity in 
renal transplantation
Use of immunosuppressive drugs after renal transplantation 
must balance between the beneﬁt of the medications in sup-
pressing rejection and their known toxicities. Nephrotoxicity 
resulting in decreased kidney function and shortened allograft 
survival is a well-known toxicity of calcineurin inhibitors, which 
has motivated researchers to investigate low-dose strategies for 
risk of rejection and loss of kidney function.
Ekberg et al. published a 12-month, randomized, open-label 
study of 1,645 renal-transplant recipients receiving one of the 
following regimens: standard-dose cyclosporine, mycophe-
nolate mofetil, and corticosteroids; or daclizumab induction, 
mycophenolate mofetil, and corticosteroids in combination 
with low-dose cyclosporine, low-dose tacrolimus, or low-dose 
sirolimus. They compared estimated glomerular ﬁltration rate 
(GFR) at 12 months and rates of both acute rejection and allo-
graft survival.
Subjects receiving low-dose tacrolimus had the highest GFR 
at 12 months (65.4 ml per minute) compared with the other 
group (range, 56.7–59.4 ml per minute) and the lowest rate of 
biopsy-proven acute rejection: 12.3%, compared with 25.8% 
in the standard-dose cyclosporine group, 24.0% in the low-
dose cyclosporine group, and 37.2% in the low-dose sirolimus 
group. Allograft survival was 94.2% in the low-dose tacrolimus 
group, 93.1% in the low-dose cyclosporine group, 89.3% in the 
standard-dose cyclosporine group, and 89.3% in the low-dose 
sirolimus group.
This study demonstrates the clinical beneﬁt of a regimen that 
includes low-dose tacrolimus and induction therapy. However, 
the comparator groups do not allow the mechanism of action 
to be identiﬁed. Also, tacrolimus may oﬀer a survival beneﬁt 
over cyclosporine, but anti-lymphocyte antibody therapy also 
may provide a beneﬁt. Among the groups receiving the low-
dose calcineurin inhibitor, those who received the calcineurin 
inhibitor itself beneﬁted the most, suggesting that the medi-
cation itself conferred the beneﬁt. However, in comparing the 
low-dose tacrolimus group with the standard-dose cyclosporine 
group, the multiple diﬀerences in types and doses of the cal-
cineurin inhibitor and use of induction therapy must be consid-
ered. Clinicians who use either tacrolimus or induction therapy 
uniformly should carefully consider how they generalize these 
beneﬁts. (N Engl J Med 2007; 357: 2562–2575)
Lynda Szczech
Combination of ACEIs and ARBs 
slow progression of kidney disease
Angiotensin-converting enzyme inhibitors (ACEIs) and angi-
otensin receptor blockers (ARBs) are two of the few main-
stays of therapy for kidney disease. The relative benefits of 
either or both in combination, though significantly studied, 
are still debated.
A new meta-analysis by Kunz et al. combines the published 
data of 49 studies with 6,181 subjects comparing ACEIs and 
ARBs, alone and combined with each other, placebo, and 
calcium-channel blocker. Not unexpectedly, both early (1–
4 months) and later (5–12 months) in the course of therapy, 
ARBs reduced proteinuria as compared with placebo or cal-
cium-channel blockers (ratio of means, 0.57 (95% conﬁdence 
interval, 0.47–0.68) and 0.69 (0.62–0.77), respectively, 1–
4 months, and 0.66 (0.63–0.69) and 0.62 (0.55–0.70), respec-
tively, 5–12 months). More clinically important, however, is the 
ﬁnding that ARBs and ACEIs reduced proteinuria to a similar 
degree (0.99 (95% conﬁdence interval, 0.92–1.05) and 1.08 
(0.96–1.22), comparing ARBs to ACEIs in the 1-to-4-month 
and 5-to-12-month time frames, respectively). Additionally, 
the combination of ARBs and ACEIs further reduced pro-
teinuria more than either agent alone (combination therapy as 
compared with ARBs, 0.76 (0.68–0.85) over 1–4 months and 
0.75 (0.61–0.92) over 5–12 months; for combination therapy 
versus ACEIs, the ratio of means was 0.78 (0.72–0.84) over 
1–4 months and 0.82 (0.67–1.01) over 5–12 months).
While degree of proteinuria is not the perfect intermedi-
ate outcome from a clinical-trial perspective, it is extremely 
important as a risk factor for progression of renal disease. 
This meta-analysis accomplishes the very important task of 
combining very small studies comparing ACEIs with ARBs, 
and their combination with each separately. The results pro-
vide answers that the individual studies did not. With the 
inherent limitations of any meta-analysis in terms of publi-
cation bias, this analysis supports an equivalence of ACEIs 
to ARBs and a superiority of combination therapy to single 
therapy in the suppression of proteinuria. Although these 
data cannot answer the natural follow-up questions of the 
Quality assessment. ACEI, angiotensin-converting enzyme inhibitor; 
ARB, angiotensin receptor blocker; CCB, calcium-channel blocker; Combi, 
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Hypoxia promotes renal 
fibrogenesis of epithelial-to-
mesenchymal transition
Renal biopsy samples from patients with chronic kidney dis-
ease typically display loss of peritubular capillaries in areas 
of tubulointerstitial ﬁbrosis. Renal hypoxia was considered a 
consequence rather than an inducer of this ﬁbrogenic proc-
ess. While recent data suggest that hypoxia may initiate the 
development and progression of renal disease, the underly-
ing molecular mechanisms by which this may occur remain 
unclear. A key mediator of cellular adaptation to low oxygen 
is hypoxia-inducible factor-1 (HIF-1). It is a transcription fac-
tor by which, in the presence of oxygen, its α-subunit (HIF-
1α) gets hydroxylated and is degraded after interaction with 
von Hippel–Lindau protein (pVHL). When oxygen is limited, 
hydroxylation of HIF-1α is inhibited, thus preventing pVHL 
interaction. HIF-1α is translocated into the nucleus, where it 
dimerizes with the β-subunit of HIF-1 to form active HIF-1 
transcription factor. To examine the role of HIF-1 in the devel-
opment of ﬁbrosis in mice, Higgins et al. inactivated HIF-1α 
in primary renal epithelial cells and in proximal tubules of 
kidneys subjected to unilateral ureteral obstruction (UUO), 
using Cre-loxP-mediated gene targeting. They found that HIF-
1α enhanced epithelial-to-mesenchymal transition (EMT) in 
vitro and induced epithelial-cell migration through upregula-
tion of lysyl oxidase genes. Genetic ablation of epithelial Hif-
1α inhibited the development of tubulointerstitial ﬁbrosis in 
UUO kidneys; this was associated with decreased interstitial 
collagen deposition, decreased inﬂammatory-cell inﬁltration, 
and reduced ﬁbroblast-speciﬁc protein-1-expressing inter-
stitial cells. Furthermore, the authors found that increased 
renal HIF-1α expression was associated with tubulointerstitial 
injury in patients with chronic kidney disease (Figure). This 
elegant series of experiments provides clinical and genetic 
evidence that activation of HIF-1 signaling in renal epithelial 
cells is associated with the development of chronic renal dis-
ease and may promote ﬁbrogenesis by increasing expression 
of extracellular matrix-modifying factors and lysyl oxidase 
genes and facilitating EMT. Moreover, these results conﬁrm 
the long-held suspicion that hypoxia is a pathogenic factor for 
renal interstitial ﬁbrosis. (J Clin Invest 2007; 117: 3810–3820; 
doi:10.1172/JCI30487)
Juan Oliver
Dietary nitrite supplementation 
protects against myocardial 
ischemia–reperfusion injury
Continuous generation of nitric oxide (NO) is essential for 
the integrity of the cardiovascular system, including the renal 
circulation and function. NO has been extensively studied 
in the setting of ischemia–reperfusion injury. For example, 
NO is likely to protect the heart, via vasodilation, in addition 
to its ability to inhibit oxidative stress, platelet aggregation, 
leukocyte chemotaxis, and apoptosis. Nitrite, an oxidative 
breakdown product of NO, serves as an acute marker of NO 
formation. Nitrite also represents a major storage form of 
NO in blood and tissues and has emerged as an endogenous 
signaling molecule with potential therapeutic implications 
for cardiovascular disease. Because steady-state levels of 
nitrite are derived in part from dietary sources, Bryan et al. 
investigated whether changes in dietary nitrite and nitrate 
modulate NO homeostasis and thereby limit the severity of 
ischemia–reperfusion injury in the myocardium (MI/R). 
They found that mice fed a standard diet with supplementa-
tion of nitrite in their drinking water exhibited higher plasma 
levels of nitrite, higher myocardial levels of nitrite, nitroso-, 
and nitrosyl-heme, and displayed a 48% reduction in infarct 
size after MI/R. Supplemental nitrate in the drinking water 
also increased blood and tissue NO products and significantly 
reduced infarct size. A time course of ischemia–reperfusion 
revealed that nitrite was consumed during the ischemic 
phase, with an increase in nitroso/nitrosyl products in the 
heart. Mice fed a diet deficient in nitrite and nitrate showed 
significantly diminished levels of nitrite in the plasma and 
heart, NO metabolites, and a 59% increase in infarct size 
after MI/R. Supplementation of nitrite in the drinking water 
reversed the effects of nitrite deficiency. These data demon-
strate the significant influence of dietary nitrite and nitrate 
on the maintenance of steady-state tissue nitrite/nitroso lev-
els and illustrate the consequences of nitrite deficiency for 
the pathophysiology of MI/R injury. Therefore, nitrite and 
nitrate may serve as essential nutrients for optimal cardio-
vascular health and may provide a treatment modality for 
cardiovascular disease. (Proc Natl Acad Sci USA 2007; 104: 
19144–19149; doi:10.1073/pnas.0706579104)
Juan Oliver
HIF-1α in renal biopsies from patients with chronic kidney disease. 
nl., normal control kidney; DN, diabetic nephropathy; gl., glomerulus. 
Asterisk indicates area with nodular sclerosis.
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